1 nts (74%) continued in remission during this
median follow-up period.
2 sentation was treated with steroids (n = 30;
median follow-up period,
29.5 months), surgical resectio
3 iod, 58 months), or was conservative (n = 5;
median follow-up period,
35 months).
4 No patients were censored before 1 year (
median follow-up period 438 days, interquartile range 17
5 d, 29.5 months), surgical resection (n = 18;
median follow-up period,
58 months), or was conservative
6 tory drugs remain in steroid-free remission (
median follow-up period,
6 months).
7 ific survival, and recurrence-free survival (
median follow-up period,
70.8 months) were not statistic
8 ted liver transplantation from 1998 to 2009 (
median follow-up period,
89 months).
9 355 patients had at least 1 follow-up visit (
median follow-up period:
9.6 months).
10 The
median follow-up period after radioembolization was 38 m
11 In this report, we extend the
median follow-up period for patient and graft survival t
12 The
median follow-up period for patients who underwent compl
13 Median follow-up periods for the DCF (n = 409), fludarab
14 With nearly 15 years
median follow-up periods,
however, these data should be
15 d at least one episode of rejection during a
median follow-up period of 1,042 days (range, 336-1,896
16 18 patients diagnosed with TAVI-PVE during a
median follow-up period of 1.4 years (interquartile rang
17 During a
median follow-up period of 1.9 years (maximum, 5.0), sym
18 During a
median follow-up period of 10 years (range, 5 to 28), 16
19 During a
median follow-up period of 10.2 years, VTE occurred in 4
20 During a
median follow-up period of 10.3 years after serum sample
21 During a
median follow-up period of 10.6 years (1994-2009), 395 c
22 During a
median follow-up period of 104.8 months (range, 3-317 mo
23 A
median follow-up period of 105.3 months (range, 12.7-286
24 f insulin resistance at baseline and after a
median follow-up period of 11.3 (range 7.3-13.4) years i
25 ings, and 59 safety communications) during a
median follow-up period of 11.7 years (interquartile ran
26 atients' clinical data were analyzed, with a
median follow-up period of 12 months (range, 2-31 months
27 Over a
median follow-up period of 12.6 years (range, 0.3-35.1 y
28 After a
median follow-up period of 13.2 years, 879 participants
29 After a
median follow-up period of 14.7 months, hepatotoxicity w
30 During a
median follow-up period of 16 years, there were 1621 CVD
31 Over a
median follow-up period of 17.9 months (interquartile ra
32 chieved a complete response relapsed after a
median follow-up period of 18 months.
33 eceived OHT, none required dialysis during a
median follow-up period of 18 months.
34 During a
median follow-up period of 19 months, patients who were
35 During a
median follow-up period of 19 years (from 1971-1975 to 1
36 Over a
median follow-up period of 19 years, 158 of the 1690 HBV
37 han a quarter of heart recipients during the
median follow-up period of 2 years.
38 Over a
median follow-up period of 2.1 years, 28% of patients tr
39 With a
median follow-up period of 2.2 years, the 2-year disease
40 al pancreatic cysts remained stable during a
median follow-up period of 2.2 years; however, in 27% of
41 cirrhosis, 61% (504 of 830) died during the
median follow-up period of 2.26 years.
42 For 2502 patients over a
median follow-up period of 2.5 years, there was no signi
43 a, with 2,397 (14.2%) receiving ADT during a
median follow-up period of 2.7 years (interquartile rang
44 Over a
median follow-up period of 2.7 years, there were no aort
45 During a
median follow-up period of 2.8 years, 13.8% experienced
46 ollowed up for a minimum of 6 months, with a
median follow-up period of 20 months.
47 Over a
median follow-up period of 20.3 months (interquartile ra
48 rction, and congestive heart failure after a
median follow-up period of 20.9 months.
49 At a total
median follow-up period of 21 months, 31 patients had di
50 After a
median follow-up period of 21 months, no residual SCLs w
51 None have had a relapse of disease, with a
median follow-up period of 21 months.
52 During a
median follow-up period of 22 years (interquartile range
53 Over a
median follow-up period of 22.2 months, overall survival
54 Americans, and 671 deaths occurred during a
median follow-up period of 22.5 years (1987-2011).
55 After a
median follow-up period of 23 months (range, 9 to 40 mon
56 ogenous causes (3.4% of the cohort) during a
median follow-up period of 23.9 years.
57 Over a
median follow-up period of 25 months, 1.3% (57 of 4347)
58 Over a
median follow-up period of 25 months, a primary end-poin
59 With a
median follow-up period of 25 months, the estimated 4-ye
60 Over a
median follow-up period of 25.5 months, no significant c
61 After a
median follow-up period of 26 months (interquartile rang
62 With a
median follow-up period of 26 months, the actuarial prob
63 After a
median follow-up period of 28 months, 52 of the 115 pati
64 During a
median follow-up period of 28 years, there were 1123 CVD
65 During a
median follow-up period of 3 years, exemestane was assoc
66 rst hospitalization (with alpha=0.03) over a
median follow-up period of 3 years.
67 n to coronary heart disease incidence over a
median follow-up period of 3.3 years among middle-aged m
68 During a
median follow-up period of 3.7 years, the primary end po
69 During a
median follow-up period of 3.9 years, participants who w
70 Over a
median follow-up period of 30 months, 789 patients (68%)
71 At a
median follow-up period of 30 months, the 3-year Kaplan-
72 During a
median follow-up period of 308 days, 61 MEs (4%) occurre
73 The recurrence rate was 3.2% at a
median follow-up period of 32 months.
74 During a
median follow-up period of 33 years, there were 45,249 m
75 receiving placebo were well matched, with a
median follow-up period of 33.0 months (interquartile ra
76 During a
median follow-up period of 34 years (range 1-45), 101 me
77 tients were randomized and assessable with a
median follow-up period of 36 months; 61 received CSA an
78 During a
median follow-up period of 36.7 months, 1929 deaths occu
79 cardia) after the initial procedure during a
median follow-up period of 36.8 months.
80 996 men, and the recurrence-free group had a
median follow-up period of 37 months (range, 1 to 168 mo
81 During a
median follow-up period of 37.2 months, venous thromboem
82 8 deaths and 1 urgent transplantation over a
median follow-up period of 396 days.
83 Over a
median follow-up period of 4 years, 6,741 (37.5%) develo
84 With a
median follow-up period of 4 years, the rate of freedom
85 regional radiotherapy are comparable with a
median follow-up period of 4 years.
86 After a
median follow-up period of 4.0 years after disease progr
87 During a
median follow-up period of 4.0 years, it was observed th
88 During the
median follow-up period of 4.1 years, the primary outcom
89 During a
median follow-up period of 4.2 years (range, 0-9 years),
90 of 326) experienced decompensation during a
median follow-up period of 4.22 years.
91 Over a
median follow-up period of 4.4 years in 7,040 patients (
92 regular Z line developed HGD or EAC during a
median follow-up period of 4.8 years (interquartile rang
93 dence interval, 0.88 to 1.06; P=0.43) over a
median follow-up period of 4.8 years.
94 After a
median follow-up period of 4.9 years, the 2-year estimat
95 In a
median follow-up period of 42 months, 55 (19%) individua
96 this cohort, 68 deaths were observed over a
median follow-up period of 42 months.
97 In a
median follow-up period of 43 months (interquartile rang
98 Over a
median follow-up period of 43 months (interquartile rang
99 With a
median follow-up period of 45 months, more than 70% of p
100 Over a
median follow-up period of 45.5 months, 269 patients (33
101 dy, and 93 mammograms were obtained during a
median follow-up period of 46 months (range, 22-58 month
102 With a
median follow-up period of 46 months, the 3-year overall
103 Over a
median follow-up period of 46 years, 508 men developed h
104 At a
median follow-up period of 46.6 months (range, 10.7 to 9
105 During a
median follow-up period of 47.2 months, advanced colorec
106 ath or cardiovascular hospitalization over a
median follow-up period of 5 years (with a range of 4 to
107 During a
median follow-up period of 5 years, treatment was succes
108 vastatin 40 mg/day or matching placebo for a
median follow-up period of 5 years.
109 After a
median follow-up period of 5.1 years, 372 subjects exper
110 Over a
median follow-up period of 5.1 years, dementia developed
111 During a
median follow-up period of 5.2 years, 203 patients died
112 a significant predictor of diabetes after a
median follow-up period of 5.2 years, and each factor re
113 37 (53%) patients experienced MACE during a
median follow-up period of 5.3 (interquartile range, 1.8
114 cedures approximately every 15 months over a
median follow-up period of 5.7 years (through September
115 After a
median follow-up period of 5.7 years, 10,766 subjects ha
116 Analysis of CEA anatomic durability during a
median follow-up period of 5.9 years identified a 7.7% f
117 With a
median follow-up period of 50 months, the 5-year CFS rat
118 ents who underwent an OVHR with mesh, with a
median follow-up period of 56 months (range, 1-156 month
119 surgery among 4036 patients with CD, with a
median follow-up period of 58 months.
120 After a
median follow-up period of 58.2 months, 668 patients (50
121 in the surgery group was 8.5% (6/70) over a
median follow-up period of 59 +/- 2.7 months for the PDT
122 (60%) no longer required opioid therapy at a
median follow-up period of 6 months.
123 th 3,871 patients enrolled onto the trial, a
median follow-up period of 6.1 years, and 437 RFS events
124 ardiovascular disease (4476 subjects) over a
median follow-up period of 6.2 years.
125 During a
median follow-up period of 6.3 years, the cumulative inc
126 At a
median follow-up period of 6.4 years, the median EFS was
127 infectious disease deaths were seen during a
median follow-up period of 6.4 years.
128 Over a
median follow-up period of 6.5 years, we identified 2593
129 were not diagnosed with lung cancer after a
median follow-up period of 6.6 years.
130 Over a
median follow-up period of 6.7 years, 106 patients died.
131 During a
median follow-up period of 6.8 years, there were 52 deat
132 At a
median follow-up period of 60 months (range, 10 to 180 m
133 n in our study did not develop LSIL within a
median follow-up period of 60 months.
134 tions in circulating fibrocyte counts over a
median follow-up period of 614 days.
135 After a
median follow-up period of 67.6 months, the primary outc
136 After a
median follow-up period of 7.4 months, the median progre
137 a total of 210 participants (6.2%) during a
median follow-up period of 7.8 years.
138 ohort free of clinical heart disease, over a
median follow-up period of 7.9 years.
139 Over a
median follow-up period of 73 months, 238 patients died
140 After a
median follow-up period of 75 months, 63 patients (74%)
141 998, 18 patients (36%+/-13%) survived with a
median follow-up period of 767 days (range, 602 to 1,127
142 ects developed chronic pancreatitis during a
median follow-up period of 78 months (interquartile rang
143 ree of disease after salvage therapy, with a
median follow-up period of 79 months.
144 After a
median follow-up period of 8 y from age 26 y, we found t
145 During a
median follow-up period of 8.0 years (through August 24,
146 During a
median follow-up period of 8.2 years, there were 285 dea
147 With a
median follow-up period of 8.3 years (range, 1.5 to 22.1
148 During a
median follow-up period of 8.4 years, 1,603 women and 95
149 deaths and 5 urgent transplantations over a
median follow-up period of 841 days.
150 During a
median follow-up period of 890 days (interquartile range
151 rt failure, and cardiovascular death) over a
median follow-up period of 9 years were assessed.
152 During a
median follow-up period of 9.3 years, 227 women (9.9% of
153 During a
median follow-up period of 9.7 years, 505 diabetes cases
154 After a
median follow-up period of 920 days, 46% of the original
155 Over a
median follow-up period of eight years, dementia develop
156 between November 2001 and July 2007, with a
median follow-up period of more than 9 years.
157 The
median follow-up period of surviving patients was 4.1 ye
158 l myocardial infarction [MI] in 27) during a
median follow-up period of three years.
159 After
median follow-up periods of 58 and 89 months (types 1 an
160 Data were collected over
median follow-up periods of 889 days (interquartile rang
161 as a negative study in that after a 7.6-year
median follow-up period,
there were no statistically sig
162 The
median follow up period was 23 months.
163 The
median follow-up period was 1.6 years for INSPIRE and 2.
164 recipient age was 63.2 (16.6) years and the
median follow-up period was 17 months (interquartile ran
165 The
median follow-up period was 186 weeks (interquartile ran
166 The
median follow-up period was 2.2 years (interquartile ran
167 The
median follow-up period was 2.4 years.
168 The
median follow-up period was 2.67 years.
169 The
median follow-up period was 20.6 months.
170 The
median follow-up period was 27 months.
171 The
median follow-up period was 28.9 months.
172 The
median follow-up period was 3.01 years.
173 The
median follow-up period was 3.21 years.
174 The
median follow-up period was 3.4 years.
175 s (interquartile range 2.7-5 years), and the
median follow-up period was 3.75 years.
176 The
median follow-up period was 3.8 years.
177 The
median follow-up period was 30 months.
178 The
median follow-up period was 32 months (range, 5-114).
179 The
median follow-up period was 37 months.
180 The
median follow-up period was 38 mo (95% confidence interv
181 The
median follow-up period was 4 years (range, 0 to 23).
182 The
median follow-up period was 4.0 years.
183 The
median follow-up period was 4.1 years.
184 The
median follow-up period was 4.6 years for mortality and
185 The
median follow-up period was 4.7 years.
186 The
median follow-up period was 4.8 years.
187 patients were included in the study and the
median follow-up period was 41 months.
188 The
median follow-up period was 43 months.
189 The
median follow-up period was 5 +/- 3.9 years (7846 patien
190 The
median follow-up period was 51.2 months.
191 The
median follow-up period was 52 months.
192 The
median follow-up period was 53 months.
193 The
median follow-up period was 6.2 years.
194 Median follow-up period was 61.9 months.
195 The
median follow-up period was 62 months.
196 The
median follow-up period was 620 days.
197 The
median follow-up period was 69 months (range, 6-126 mont
198 classified 6 months after presentation, the
median follow-up period was 7.2 years (quartiles at 6.2
199 The
median follow-up period was 7.2 years.
200 8 months (range 4 months-19 years), and the
median follow-up period was 8 years (range 3 months-18 y
201 The
median follow-up period was 8.2 years.
202 total follow-up of 162,974 person-years (the
median follow-up period was 8.5 years).
203 The
median follow-up period was 84 months (range 32-106 mont
204 The
median follow-up period was 9.1 years.
205 The
median follow-up period was 9.3 years (range 0.1 to 23.6
206 The
median follow-up period was 9.4 years.
207 The
median follow-up period was 9.8 years.
208 The
median follow-up periods were 28.4 and 27.4 mo for i-PET